Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global man-made vascular graft market was valued at USD 3,684 million in 2024 and is projected to reach USD 5,509 million by 2031, exhibiting a compound annual growth rate (CAGR) of 6.1% during the forecast period.
Man-made vascular grafts, also known as synthetic vascular prostheses, are medical devices designed to replace, bypass, or maintain function of damaged, occluded, or diseased blood vessels. These artificial conduits are critical in vascular surgery and are manufactured in small, medium, and large diameters to match the specific anatomical requirements of procedures. The most common materials used include expanded polytetrafluoroethylene (ePTFE), polyester (Dacron), and polyurethane, each offering distinct properties related to biocompatibility, porosity, and long-term patency.
The market growth is primarily driven by the rising global prevalence of cardiovascular diseases and peripheral arterial disease, coupled with an aging population that is more susceptible to vascular conditions. Furthermore, technological advancements in graft materials, such as the development of bioactive coatings that reduce thrombosis and improve endothelialization, are creating significant opportunities. However, the market faces challenges, including the high cost of advanced grafts and the risk of complications like infection and graft failure. Key players, such as Getinge, Terumo, and BD (Bard PV), dominate the competitive landscape, collectively holding over 65% of the global market share, and are actively engaged in research to introduce next-generation products.
Rising Prevalence of Cardiovascular Diseases and Lifestyle Disorders
The global burden of cardiovascular diseases, including Peripheral Artery Disease (PAD) and aortic aneurysms, is a primary catalyst for the man-made vascular graft market. The increasing incidence of conditions like diabetes and hypertension, which are major risk factors for vascular diseases, is expanding the patient pool requiring surgical interventions such as bypass procedures. An aging global population is further amplifying this demand, as elderly individuals are more susceptible to vascular complications.
Technological Advancements in Graft Materials and Design
Continuous innovation in biomaterials is a significant driver. The development of advanced polymers like expanded polytetrafluoroethylene (ePTFE) and polyurethane, along with bio-hybrid grafts that incorporate biological components to enhance biocompatibility, is improving patient outcomes. These next-generation grafts offer superior patency rates, reduced risk of infection, and better compliance, making them more appealing to vascular surgeons.
➤ The global vascular graft market is projected to grow steadily, with a significant portion of this growth attributed to the increasing adoption of innovative synthetic grafts for haemodialysis access and complex arterial reconstructions.
Furthermore, the shortage of suitable autologous veins for bypass surgeries, particularly in repeat procedures or patients with compromised vasculature, creates a substantial and sustained need for reliable synthetic alternatives. This clinical necessity ensures a consistent baseline demand for man-made vascular grafts.
MARKET CHALLENGES
High Cost and Procedural Complexities
The high cost of advanced synthetic vascular grafts and the associated surgical procedures can limit their adoption, especially in cost-sensitive healthcare systems and developing regions. The surgeries themselves are complex, requiring highly skilled vascular surgeons, which can constrain market growth in areas with limited access to specialized healthcare infrastructure.
Other Challenges
Risk of Graft Failure and Complications
Despite advancements, man-made grafts are still associated with risks such as thrombosis (clotting), intimal hyperplasia (tissue overgrowth at the suture sites), and infection. These complications can lead to graft failure, requiring re-intervention and posing a significant challenge to long-term patient management and market acceptance.
Stringent Regulatory Hurdles
The path to market for new vascular grafts involves rigorous regulatory scrutiny from bodies like the FDA and EMA to ensure safety and efficacy. The extensive clinical trials and documentation required can lead to prolonged development timelines and high R&D costs, acting as a barrier for new market entrants.
Competition from Alternative Treatment Modalities
The growth of the man-made vascular graft market is restrained by the increasing preference for minimally invasive endovascular procedures, such as angioplasty and stenting, for certain vascular conditions. These alternatives often offer shorter recovery times and lower immediate risks compared to open surgical graft implantation, diverting a portion of the patient population away from traditional graft procedures.
Limitations in Small-Diameter Graft Performance
A significant technical restraint is the suboptimal performance of synthetic grafts in small-diameter applications (less than 6mm), such as coronary artery bypass. In these cases, autologous veins remain the gold standard due to their superior patency rates. The inability of current synthetic grafts to fully replicate the biological properties of natural blood vessels limits their use in a substantial segment of the vascular surgery market.
Expansion in Emerging Markets
Emerging economies in Asia-Pacific, Latin America, and the Middle East present significant growth opportunities. Rising healthcare expenditure, improving healthcare infrastructure, and growing awareness of vascular diseases are expected to drive adoption. Market players can capitalize on this by offering cost-effective products and establishing local manufacturing and distribution networks.
Development of Bioengineered and Tissue-Engineered Grafts
The frontier of opportunity lies in the research and development of next-generation bioengineered vascular grafts. These include grafts seeded with a patient's own cells (tissue-engineered vascular grafts) or those with bioactive coatings that promote endothelialization and resist clotting. Success in this area could revolutionize treatment, particularly for small-diameter applications, unlocking a massive new market segment.
Focus on Outpatient and Ambulatory Surgical Centers
The shifting trend towards performing vascular procedures in outpatient or ambulatory surgical centers creates an opportunity for grafts and associated devices designed for less invasive implantation techniques. Products that facilitate faster procedures, promote rapid healing, and reduce hospital stays are well-positioned to capture value in this evolving care setting.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
ePTFE Man-made Vascular Graft is the dominant product segment, favored for its exceptional biocompatibility, durability, and proven long-term performance in clinical settings. Its microporous structure facilitates excellent tissue integration and reduces the risk of complications, making it the preferred choice for a wide range of vascular reconstruction procedures. Innovation in this segment focuses on developing grafts with enhanced healing characteristics and reduced thrombogenicity to improve patient outcomes. |
| By Application |
|
Cardiovascular Diseases represents the leading application segment, driven by the high global prevalence of conditions requiring vascular bypass or replacement, such as coronary artery disease and peripheral arterial disease. The consistent demand is supported by the critical nature of these procedures in saving limbs and lives. The Aneurysm application is another major area, with grafts being essential for the surgical repair of aortic and other arterial aneurysms, where the primary goal is to prevent life-threatening ruptures. |
| By End User |
|
Hospitals are the primary end-users, as they possess the comprehensive infrastructure, specialized surgical teams, and intensive care facilities required for complex vascular surgeries. These institutions handle the majority of elective and emergency procedures, from routine bypasses to complex aortic repairs. While Ambulatory Surgical Centers are growing for less complex interventions, hospitals remain the central hub due to their capacity for managing post-operative care and potential complications associated with major vascular graft implantations. |
| By Vessel Diameter |
|
Large-Diameter Grafts are the leading segment, extensively used for aortic repairs and major vessel bypasses where high blood flow rates are critical. These grafts have a well-established safety and efficacy profile. The segment for Small-Diameter Grafts presents significant ongoing research challenges, as achieving long-term patency in coronary and below-the-knee bypass procedures remains a key focus for innovation, driving development in bioactive and tissue-engineered graft technologies. |
| By Material Innovation |
|
Standard Synthetic Grafts currently dominate the market due to their reliability, availability, and proven track record. However, the most dynamic growth and research interest lie in the Bio-hybrid/Bioactive Grafts segment. These advanced grafts are designed with coatings or impregnations, such as heparin or collagen, to enhance biocompatibility, reduce thrombogenicity, and improve healing, addressing key limitations of standard grafts and representing the future direction of product development. |
A Consolidated Market Dominated by a Few Global Leaders
The global market for Man-made Vascular Grafts is characterized by a high degree of consolidation, with the top three players Getinge, Terumo, and Bard PV (a subsidiary of BD) collectively commanding over 65% of the market share. This dominance is a testament to their extensive product portfolios, robust global distribution networks, strong brand recognition, and continuous investment in research and development. The market is primarily driven by the high prevalence of cardiovascular diseases and aneurysms, which together account for over 60% of application demand. ePTFE (expanded polytetrafluoroethylene) Vascular Grafts represent the dominant product type, holding a majority share of over 50% due to their excellent biocompatibility and performance characteristics in various vascular procedures.
Beyond the leading trio, the market includes several other significant players that compete effectively in niche segments or specific geographic regions. Companies such as W. L. Gore & Associates are major innovators, particularly in advanced ePTFE technologies. Established medical device manufacturers like B. Braun and LeMaitre Vascular have a strong presence with specialized vascular product lines. Furthermore, regional manufacturers, including Junkne Medical, Suokang, and Chest Medical in the Asia-Pacific region, are increasingly important, contributing to the competitive dynamics and catering to the growing demand in emerging markets. These companies often compete on factors such as product customization, cost-effectiveness, and regional support services.
List of Key Man-made Vascular Graft Companies ProfiledGetinge
Junkne Medical
Suokang
Chest Medical
Medtronic plc
Endologix LLC
Perouse Medical (a Getinge Company)
CryoLife, Inc.
Vascular Grafts Solutions Ltd.
The global Man-made Vascular Graft market is on a robust growth trajectory, projected to increase from a valuation of $3684 million in 2024 to $5509 million by 2031, representing a compound annual growth rate (CAGR) of 6.1%. This sustained expansion is primarily fueled by the increasing global incidence of cardiovascular diseases and aneurysms, which together account for over 60% of the market's applications. The aging global population and rising risk factors such as hypertension and diabetes are key contributors to the growing patient pool requiring vascular interventions. The market's resilience is further underpinned by the critical nature of these medical devices in replacing or bypassing damaged blood vessels, making them indispensable in modern vascular surgery.
Other TrendsMaterial Innovation and ePTFE Dominance
A dominant trend within the market is the material composition of the grafts. Expanded Polytetrafluoroethylene (ePTFE) Vascular Grafts are the leading product type, holding over 50% of the market share. This material is preferred for its excellent biocompatibility, durability, and ease of handling during surgical procedures. The market also includes segments for Polyester and PTFE grafts, but continuous research and development efforts are focused on enhancing the properties of ePTFE to improve long-term patency rates and reduce complications such as thrombosis and intimal hyperplasia.
Consolidated Competitive Landscape and Regional Market DynamicsThe competitive landscape is characterized by a high degree of consolidation, with the top three players Getinge, Terumo, and Bard PV collectively holding over 65% of the global market share. This concentration drives intense competition centered on product innovation, strategic mergers, and geographic expansion. Regionally, Asia-Pacific and North America are the primary markets, accounting for approximately 70% of global demand. The growth in Asia-Pacific is particularly significant, driven by improving healthcare infrastructure, increasing medical expenditures, and a large patient population. These regional dynamics are crucial for manufacturers developing their long-term growth strategies.
Regional Analysis: Man-made Vascular Graft MarketEurope
Europe represents a mature and significant market for man-made vascular grafts, characterized by advanced healthcare systems and a high standard of surgical care. Countries such as Germany, France, and the United Kingdom are at the forefront, with strong adoption of endovascular aortic repair techniques. The market is influenced by centralized procurement processes and stringent CE marking regulations that ensure product safety and efficacy. While reimbursement levels can vary between national health services, there is a general trend towards funding innovative therapies that demonstrate long-term cost-effectiveness. The region shows a growing preference for bioactive grafts that promote better healing and reduce complication rates. Collaboration between academia and industry is strong, fostering development in areas like small-diameter grafts for coronary applications.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for man-made vascular grafts, propelled by rapidly improving healthcare infrastructure, rising healthcare expenditure, and a growing middle class. Japan and Australia have well-established markets, but the most dynamic growth is occurring in China and India, where increasing rates of diabetes and hypertension are expanding the patient population requiring vascular interventions. Market access is expanding as more hospitals gain the capability to perform complex vascular surgeries. Local manufacturers are increasingly active, offering cost-competitive products, while international companies are investing heavily to capture this high-growth potential. Regulatory harmonization efforts across the region are gradually simplifying market entry for new graft technologies.
South America
The South American market for man-made vascular grafts is emerging, with growth potential tied to economic development and healthcare modernization. Brazil is the largest market, driven by a sizable population and an increasing focus on improving public and private healthcare coverage. The adoption of advanced grafts is currently concentrated in major urban centers and private hospitals. Market growth is challenged by economic volatility and budget constraints within public health systems, which can limit access to higher-priced, innovative grafts. Nonetheless, there is a clear trend towards upgrading surgical capabilities and training vascular surgeons, which is expected to steadily increase demand over the coming years.
Middle East & Africa
The Middle East and Africa region presents a heterogeneous market with vast disparities in healthcare access. Wealthier Gulf Cooperation Council countries, such as Saudi Arabia and the UAE, have advanced medical facilities and exhibit demand patterns similar to developed markets, including the use of premium-priced grafts. In contrast, much of Africa faces significant challenges, including limited healthcare infrastructure and funding, resulting in lower penetration of synthetic grafts. The market growth is primarily driven by the Gulf states, where medical tourism and government investments in flagship hospitals are creating centers of excellence for cardiovascular care. Across the region, there is a growing recognition of the burden of vascular diseases, prompting initial steps towards market development.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2031. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Medical device manufacturers
Healthcare providers and hospital systems
Contract research organizations
Investors, consultants, and policy makers
-> Global man-made vascular graft market was valued at USD 3,684 million in 2024 and is projected to reach USD 5,509 million by 2031.
-> Key players include Getinge, Terumo, Bard PV, W. L. Gore, and B.Braun, among others.
-> The market is expected to grow at a CAGR of 6.1% during 2024-2031.
-> Asia-Pacific and North America collectively hold about 70% of the global market share.
-> ePTFE Vascular Graft dominates with over 50% market share, followed by Polyester grafts.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates